Unknown

Dataset Information

0

The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques.


ABSTRACT: The induction of a robust neutralizing antibody (nAb) response is likely to be as essential as specific cell-mediated immunity (CMI) against multiple antigens for the development of effective preventive and therapeutic vaccines against hepatitis C virus (HCV) infection in humans. To date, no data on the immunogenicity of the replication-defective vaccinia virus (derived from the Tiantan strain) (rNTV)-based HCV vaccine in primates have been reported. This study describes in detail the immunogenicity of various vaccine candidates in rhesus macaques, including rNTV-based and replication-defective recombinant adenoviral (rAd)-based HCV vaccines, as well as HCV pseudotyped virus-like particles (HCVpp). Our data showed that rAd-HCV vaccine boosting induced robust CMI, while priming or boosting with HCVpp enhanced the antigen-specific nAb response after rAd-HCV vaccination; however, CMI was not enhanced. Vaccination includes rNTV-HCV priming induced robust antigen-specific antibody, particularly nAbs, and CMI responses. Furthermore, more robust and longer-lasting CMI and higher cytokine levels (both Th1 and Th2 types, especially IFN-?) resulted from boosting with rAd-HCV. We conclude that the rNTV-based HCV vaccine induces robust nAbs and CMI when combined with a heterogeneous primer-booster strategy, which shows promise for development of a human HCV vaccine.

SUBMITTER: Wen B 

PROVIDER: S-EPMC3776631 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques.

Wen Bo B   Deng Yao Y   Chen Hong H   Guan Jie J   Chuai Xia X   Ruan Li L   Kong Wei W   Tan Wenjie W  

Molecular therapy : the journal of the American Society of Gene Therapy 20130618 9


The induction of a robust neutralizing antibody (nAb) response is likely to be as essential as specific cell-mediated immunity (CMI) against multiple antigens for the development of effective preventive and therapeutic vaccines against hepatitis C virus (HCV) infection in humans. To date, no data on the immunogenicity of the replication-defective vaccinia virus (derived from the Tiantan strain) (rNTV)-based HCV vaccine in primates have been reported. This study describes in detail the immunogeni  ...[more]

Similar Datasets

| S-EPMC5671601 | biostudies-literature
| S-EPMC3625194 | biostudies-literature
| S-EPMC7098914 | biostudies-literature
| S-EPMC3698190 | biostudies-literature
| S-EPMC3367646 | biostudies-literature
2023-12-01 | GSE221653 | GEO
| S-EPMC9151762 | biostudies-literature
| S-EPMC5437729 | biostudies-literature
| S-EPMC3247638 | biostudies-literature
| S-EPMC7067952 | biostudies-literature